Roth Capital Has Bullish Estimate for Cingulate Q1 Earnings

Cingulate Inc. (NASDAQ:CING) – Investment analysts at Roth Capital increased their Q1 2025 earnings estimates for shares of Cingulate in a report released on Monday, March 31st. Roth Capital analyst B. Pachaiyappan now expects that the company will earn ($0.96) per share for the quarter, up from their prior forecast of ($2.19). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Roth Capital also issued estimates for Cingulate’s Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($2.68) EPS and FY2026 earnings at ($2.48) EPS.

CING has been the topic of several other reports. Roth Mkm started coverage on Cingulate in a research report on Friday, January 10th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Cingulate in a report on Thursday, March 6th.

Cingulate Trading Down 1.2 %

Shares of NASDAQ:CING opened at $4.25 on Wednesday. The firm has a market cap of $13.65 million, a price-to-earnings ratio of -0.29 and a beta of -0.83. Cingulate has a 1 year low of $1.80 and a 1 year high of $20.83. The business has a fifty day simple moving average of $4.26 and a 200 day simple moving average of $4.43.

Hedge Funds Weigh In On Cingulate

Several institutional investors have recently bought and sold shares of CING. AlphaMark Advisors LLC boosted its stake in shares of Cingulate by 50,000.0% during the 4th quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock worth $25,000 after acquiring an additional 5,000 shares in the last quarter. Jane Street Group LLC acquired a new stake in Cingulate in the 3rd quarter worth approximately $106,000. Geode Capital Management LLC bought a new stake in Cingulate during the fourth quarter worth approximately $135,000. Finally, Commonwealth Equity Services LLC raised its position in shares of Cingulate by 281.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock valued at $212,000 after purchasing an additional 31,746 shares during the period. 41.31% of the stock is currently owned by institutional investors.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.